Navigation Links
Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
Date:6/14/2010

MAPLE GROVE, Minn., June 14 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. today announced the initiation of a global Phase III clinical trial for USL255 (extended-release topiramate), an internally developed program for the management of epilepsy in adults, using the company's proprietary formulation technology.  USL255 is designed to provide convenient once-daily dosing and reduce fluctuations in topiramate blood levels observed with currently available topiramate options.

"The initiation of the Phase III trial for USL255 is a key milestone in Upsher-Smith's vision of becoming a leader in the CNS field," said Alan Rauch, M.D., Chief Medical Officer and Vice President Medical & Regulatory Affairs.  "There is a significant unmet need in the treatment of epilepsy, with as many as 30 percent of patients not adequately controlled using current antiepileptic drugs.  Poor medication compliance may be a contributing factor, and we are excited about the potential for USL255 to offer patients and clinicians a new treatment option with the potential for improved compliance."

The Phase III trial is a randomized, multinational, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of USL255 in patients 18 to 75 years of age with refractory partial-onset seizures with or without secondary generalized seizures.  Further information on this clinical study can be found at http://www.clinicaltrials.gov/ct2/show/NCT01142193?term=upsher&rank=2.

USL255 is the lead investigational drug in Upsher-Smith's expanding CNS development pipeline that includes two other investigational drug programs.  In April 2010, the company obtained exclusive rights in North America for the investigational drug tonabersat, a first-in-class neuronal gap junction modulator. Based on results of preclinical models of seizures, Upsher-Smith will focus on development of tonabersat for the treatment of epilepsy. In July 2008, Upsher-Smith entered into a worldwide licensing agreement with Proximagen Neuroscience Plc for the development and commercialization of the PRX1 program for the symptomatic treatment of Parkinson's disease.

About Epilepsy and Parkinson's Disease

Epilepsy is a neurological condition that produces seizures affecting a variety of mental and physical functions.  Almost three million people in the U.S. have some form of active epilepsy with about 200,000 new cases of epilepsy diagnosed each year.(1)

Parkinson's disease is a chronic, progressive neurodegenerative disease that causes impairment in motor function, as well as many non-motor complications throughout the various stages of the disease.  As many as 1 million people in the U.S. suffer from Parkinson's disease, with 1 in 100 people over the age of 60 affected.(2)

About Upsher-Smith

Upsher-Smith Laboratories, Inc., founded in 1919, is a rapidly growing, privately held pharmaceutical company that develops, manufactures, and markets prescription and over-the-counter products.  Upsher-Smith's product portfolio focuses in the areas of women's health, dermatology, cardiology, and central nervous system diseases.  The company's growing CNS pipeline concentrates on diseases with significant unmet need, including epilepsy and Parkinson's disease.  To expand its CNS pipeline, Upsher-Smith seeks alliances and co-development programs, pursues licensing and acquisitions, and leverages the development of its core competency in formulation development.  For more information, visit www.upsher-smith.com.

1. Epilepsy Foundation. Available at: http://www.epilepsyfoundation.org/.  Accessed on May 19, 2010.

2. The Michael J. Fox Foundation for Parkinson's Research. Available at: http://www.michaeljfox.org/.  Accessed on May 19, 2010.


'/>"/>
SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Upsher-Smith Introduces New Formulation of PreNexa® Prenatal Vitamins
2. Upsher-Smith Announces New Formulation of PreNexa(R) Prenatal Vitamins
3. Upsher-Smith Announces Milestone in Development of CNS Strategy
4. New Data: Cholesterol Management Analysis of Upsher-Smiths Slo-Niacin(R) Tablets in Combination with Lipitor(R)
5. Dr. Chunhao Zhang Joins Asymchem Laboratories
6. Watson Confirms Columbia Laboratories Filing of Definitive Proxy Relating to Watsons Acquisition of U.S. Rights to CRINONE® Progesterone Gel Product Line
7. Perrigo Acquires Rights to Generic Version of HalfLytely® from Novel Laboratories
8. Health Network Laboratories (HNL) Enters Into License Agreement With Hunter Laboratories to Provide HunterHeart Cardiovascular Disease Management Program.
9. Forensic Laboratories Selected for Colorado Companies to Watch Award
10. Kettering Health Network Partners With DIATHERIX Laboratories To Improve Quality, Efficiency of Care
11. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Eloxatin(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016  SciClone Pharmaceuticals, Inc. ... it has entered into a settlement agreement with ... fully resolving the SEC,s investigation into possible violations ... the terms of the settlement agreement, SciClone has ... including disgorgement, pre-judgment interest and a penalty.  This ...
(Date:2/4/2016)... Feb. 4, 2016 Global Immunology Market ... to drive long-term market growth Summary ... of chronic disorders that affect 5–7% of western ... of their symptoms and key patient demographics, they ... immune pathways and an inappropriate immune response. Generally, ...
(Date:2/4/2016)... DIEGO, Feb. 4, 2016  Aethlon Medical, Inc. ... affinity biofiltration devices to treat life-threatening diseases, today ... 2016 ended December 31, 2015. ... objectives set forth in our last quarterly call, ... reinforce our long-term objective to establish the Aethlon ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... 2016 , ... Love is in the air at King Kullen! The local ... packaging. This staple for Valentine’s Day is a must-have, and can be picked up ... not only are long-stem roses available, but also other flower bouquets, elegantly wrapped and ...
(Date:2/5/2016)... MN (PRWEB) , ... February 05, 2016 , ... The ... at the Day Block Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund ... Larry Schneiderman, owner of Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect ...
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University ... Allen have signed a joint enrollment and degree completion agreement. The agreement, ... and baccalaureate degrees at FHU|Dickson. , The agreement allows students to be ...
(Date:2/5/2016)... ... February 05, 2016 , ... In the ... the country gathered at the La Valencia Hotel in San Diego, California to ... was named the year’s most outstanding franchise, walking away with the coveted David ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Boar’s Head Brand®, ... in time for this weekend’s Big Game. Take the stress out of your party ... keep your guests happy at every stage of the game. , “The key to ...
Breaking Medicine News(10 mins):